Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is positioning itself at the intersection of artificial intelligence and precision medicine, aiming to transform the early detection and diagnosis of coronary heart disease. The company’s proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including nonobstructive forms that conventional diagnostic methods may miss. This approach addresses a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050, according to recent industry estimates.
The company offers two blood-based tests: Epi+Gen CHD and PrecisionCHD. These tests leverage epigenetics and genetics to provide a more comprehensive risk assessment. Cardio Diagnostics has strengthened its commercialization efforts by securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, which facilitate broader adoption by healthcare providers. Additionally, the company has expanded U.S. provider partnerships and launched its first international expansion in India, signaling a commitment to global reach.
With a proprietary, AI-driven platform that has achieved reimbursement milestones and growing provider adoption, Cardio Diagnostics occupies a scientifically grounded and commercially actionable position in the diagnostics landscape. The company’s technology is designed to detect what traditional tools miss, potentially improving outcomes for patients who might otherwise be undiagnosed. For more information, visit the company’s website at https://cdio.ai/.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO. For further details on the company’s technology and market strategy, the full article can be accessed at https://nnw.fm/9LJ2r.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging its proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease, aiming to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
